₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3
|
|
|
- くにひと かたづ
- 4 years ago
- Views:
Transcription
1 ₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3 3, 3..,.. 2 ₂ ₁ 1, 1, 1, 1, 1, 1, 1, 1, 3, 2 1, 2, 3,., ,,,.3 A,,..,,,. 3. ₂ ₂ 1 1, 2, 2, 2, 2, 1, 1, 2 1, 2. 1
2 ₂ ₃ 1 1, 1, 1, 1, 1, 1, 2, 2, 1, 1 1, CRT-D,7 2.1, Staphylococcus epidermidis,, CRT-D. TEE mm, 10 6 mm,20 10 mm. 9 CRT-D,,10 mm. 2 TEE, 6 TEE.TEE. ₂ ₄,,,,,, 48..,., 58, ,., 18. 6,. ST.,,,.,. 3 ₃ ₁ 1,,,,,,,,, 40,.1,.,...,.,,,. A 1 stage,.,,.,,.. ₃ ₂,,,,,, 45. CT 20 mm.mri T 2 WI, CT,.,,.EUS,,,.,,.IgG4,PSL. FDG-PET SUVmax: 3. 08,., S ,.,. ₃ ₃ 1, 1, 1 2, 1 3, 4 1, 2, 3, 4., mm..b, SPN,. CT,, 15 mm. CT,.,. B,. ₃ ₄ 1, 1, 1, 1, 1, 2 1, 2 66,.,.TSH IU/ml,FT ng/ ml,ft pg/ml,tgab 210 IU/ml,TPOAb 600 IU/ml, I,TSH IU/ml,FT ng/ml,ft pg/ ml,,. TRAb IU/l,TSAb 3, TSH IU/ml,FT ng/ml,ft3 2
3 0. 26 pg/ml, T4.. 1 ₁ ₁ 1 1, 1, 1, 1, 1, 1, 1, 2, 1 1, mm.1 17 mm, CT. 39 mm 2.,,. HBs HCV. CT,., steatohepatitis Stage 1 Graide 1 NASH... ₁ ₂ , 1, 2, 1, 1, 1, 1, 1, 1, 1 1, 2 C SVR., SVR 17 C C,1999.Genotype 2a,HCV-RNA 6 IFN.SVR S 5 25 mm. US CT MRI,Child A., clear cell type. F 1 /A 1.C SVR 15. ₁ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 2, 3 1, 2, 3 78,.C.., S 4 20 mm,3. S 4 28 mm.,,.,..,ki-67,l-fabp,gs,β-catenin,saa,crp, I-HCA. HCA. I-HCA,,SAA SAA-HN. ₁ ₄ 1, 1, 2, 2, 2, 3, 3, 3, 4 1, 2, 3, 4 24.,.,,.,,..Sonazoid CEUS 3,,. focal nodular hyperplasia FNH,CT MRI,Gd-EOB-DTPA FNH., fibrolamellar hepatocellular carcinoma FLC. FLC CEUS. ₁ ₅,,,,,,,,,, TACE CEUS.,TACE CT CEUS,. TACE 146. CT, CEUS., 1. RECICL CT TE 4,CEUS TE 3.1 CT 17 TE 3. CEUS,. 3
4 2 ₂ ₁ 1 1 1, 2, 1, 2, 1 2, 3 1, 2, 3 HCC. 50,,. 30,. S 3 20 mm,..., Washout. EOB-MRI.,,HMB 45., 1. ₂ ₂ 1 2 1, 2, 1, 2, 1 2, 3 1, 2, 3 HCC noduleinnodule. 60, 2,US. US, S 8 27 mm,,,, nodule in nodule,. CT,EOB- MRI,,., HMB45,. nodule in nodule, 1. ₂ ₃,,,,, haml,,,., HCC, HCC.. haml haml 8 3, 5, , 36 mm mm, 5, 2, 1. 5, 2, 1, 4, 4.B 1. 5, 2, ₂ ₄ 1 1, 1, 1, 1, 1 2, 2, 2 3, 3, 3, 4 1, 2, 3, 4 41,..CT 8 cm.. 8 cm 6 cm.,,,..,,..,...,.,.,,. ₂ ₅ 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 71,.C 7,., CT.CT,. 34 mm.,, wash out,,.,,igg,cd20,cd79a,mum-1,cd138, bcl-1,.,.. ₂ ₆ 1, 2, 2, 1 1, 2 Focal nodular hyperplasia FNH B.FNH,,,B,. FNH
5 85 50, 38 28, mm 18 mm,b, FNH,,. 3 ₃ ₁ 1, 1, 1, 1, 1, 1, 3, 2, 2, 1 1, 2, 3 GE B US,,.,., 2. 71,ALC CT L/Sp 0. 85,US,2 L/ Sp 1. 25,US, 4,L/Sp 0. 65,US. 33,CH-C ,US,, ,US ₃ ₂ 1, 2, 1 2. ₃ ₃,,,,,,,,,,,.,, SOL,SWE SWE 60, SOL 15. l,sol.,,,,..,.,.,. SOL. ₃ ₄ 1 1, 1, 2, 2, 1, 1, 1, 1, 1, 1 1, 2 Child-Pugh C ,3 MELD score MELD , , C-P C , VTQ 4. 23, C-Pscore 13,MELDscore 30., , VTQ, ₃ ₅,,,,,,,,,,C DAAs, SVR., DAAs share wave elastography SWE. DAAs, SWE 30.SWE,. GE LOGIQ E9, Aplio500.., SWE. SWE.,DAAs, DAAs,. ₃ ₆,,,,,,,,,,., 1 / 3 Regev. 2012,.SWE B,. 5
6 SWE 30. 3,3, Transient elastography TE. LOGIQ E9 GE.,,,..TE,3,. SWE. ₃ ₇ 3 1, 1, 1, 1, 1, 2, 2, 2, 3, 1 1, 2, 3 Fontan,.,., 21 24, 23 25, Fontan 10, ,. CT,.,. ₃ ₈ 1, 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2, ROI. ROI,. 30.LOGIQ S8 GE. Fibroscan echosens.roi.,metavir score,,. METAVIR score,. ROI,. 4 ₄ ₁ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 80, , US,., US US sludge, US,. 2 3 US,,. US..,.,.,. 25,. ₄ ₂ 1 1, 1, 1, 1, 1, 1, 2, 2, 3 1,, , US, 4 mm, US US, 6 mm,,. US,., 60 mm, mp T1b.,,... ₄ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 40,.,.,. Rokitansky-Ashoff sinus 6
7 ,. 25 mm.,.,,.., 30 mm...,.. ₄ ₄ 1,,,,,,,,, 40,.2.1, PD-1.,,., 27 mm.,,,,.,mri,t 1 WI,T 2 WI,, PET-CT FDG ,. 28 mm,,.. ₄ ₅ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 80, 20,12. ALP, GTP,CT. US RHD,LHD,B 2,B 3,B 4,Bc,Bs 24 mm.lhd,b 2, B3,B4,.RHD Bs,.. CT 22 mm,. LHD B 4,.,.,. ₄ ₆ 1, 2, 3, 5, 4, 6, 7, 3 1, 2, 3, 4, 5, 6, 7. ₄ ₇ 1 1, 1, 1, 1, 1, 2, 2, 3 1, 2, 3 66,..,. CT MRCP.,.ERCP,,..,.. B 6,B 7,.,..,.,. 5 ₅ ₁ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 70,. ESD, ESD. CA ,CT..24 mm,,,,....,.,.,.,... 7
8 ₅ ₂ 1 1 3, 1 3, 2, 3 1 JA, 2 JA, 3 IPMN US. US. 5 mm,, 3,, D 2. CT MRI CT MRI,IPMN.. US,IPMN.,. IPMN 1. ₅ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2,WHO Intraductal papillary-mucinous neoplasm IPMN ITPN.ITPN, IPMN 1.,ITPN CT. 63 mm.,,., 11 mm.vater.,ipmn ITPN. ITPN.. ₅ ₄ 1 1, 1, 1, 2, 2, 3, 1 1, 2, 3 pnet US,., pnet , SPN. US mm.,.,. CT.,.,pNET. pnet,,. 1. ₅ ₅ 1, 1, 2 1, 2. ₅ ₆ 1 1, 1, 1, 1, 1, 1, 2, 2, 3, 3 1, 2, 3 77,. US,,. US mm.,,.,,. CT,. MRI T 1,T 2,,dynamic., , 1. 3.,,,.. 6 ₆ ₁ 1,,,,,,,,, 70. SMT,.,, 60 mm Delle SMT.,., strong echo,delle. 8
9 ,.GIST malignant potential SMT,., hyperchromatic. Chromogranin,Ki67 index 2 NET G1.6 cm,. ₆ ₂ 1 1, 1, 1, 1, 2, 2, 2, 3, 3, 4 1, 2, 3, 4 73,..,,.., SS., M, SM. Bmode,..,. ₆ ₃ 1 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 NET., NET. 40,.3, 9 cm. 10 cm,,, 12.,., NET.,. ₆ ₄ 1, 1, 2, 3 1, 2, 3 60.,.,,,.. 2, 1,., 3..,. ₆ ₅ 1, 1, 1, 1, 2, 2, 3, 3 1, 2, , CT,US.,,. 29 US,CT 12,CT 10,US 1, 6, 23 CT,US 9,CT 9,US 5,US 5, 15 US,CT 2,CT 13,US 0, 12 CT,US 6, CT 5,US 1.,CT US,US. CT,US,. ₆ ₆ 1, 1, 1, 2, 2 1, 2,,.,,., 30, , 3 2.,,,, UP.,,,. 9
10 ₆ ₇ 1, 1, 1, 2, 2 1, 2,,,.,,., 3 3, cm 188 cm, ,,. 1 ₁ ₁ 1, 2 1, ,,.,.,Ⅰ,Ⅱ, 1989,.,.,,. ₁ ₂ 1 1, 2, 1, 1, 1, 1, 1, 2, 2 1, TTE,,.TTE., TEE,.. CT PLSVC, CS. CS,.CS PLSVC, CS,PLSVC. ₁ ₃ 2 1, 2, 1, 1, 1, 1, 1, 2, 3, 2 1, 2, MR,TR,Af,,. 6,.CT MRI,,., MsR,TR,Af,,.5, CT,.,.MRI,.,,. 2,. ₁ ₄ 1 1, 1, 1, 1, 1, 1, 2 1, 2 47.,..,,.,,.. CT.,,. PPI proton pump inhibitor,,.1,., CT..CT.2,. ₁ ₅,,,,,, 72.,,.,, 35., mmhg,.,,..,, dip and plateau pattern, CP,. 10
11 ... ₁ ₆ 1 1, 4, 1, 1, 3, 3, 3, 2, 2 1, 2, 3, 4 Superb Micro-vascular Imaging SMI, CT,. 84,, EVAR,, Type Ⅱ,. CT,,, SMI.,. SMI.EVAR, SMI. 2 ₂ ₁ 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 72,.., 7 mm...,,..... ₂ ₂ 1, 2 1, 2 45, A.,,,,.,,,.,..,,,. ₂ ₃ 1 1, 2, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 67,.,,. 10 mm, 35 mm.,.,..,.,,,.. ₂ ₄ 1 1, 1, 1, 1, 1, 1, 2, 1 3 1, 2, km,2. ST,.,. 80,, 2 m s 15.,, 6 90,.,. ₂ ₅ 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 24, 19,.20 11
12 .. 1,,., mm,, 22 mmhg.,.,, 4., 2. 3.,,,.,. 3 ₃ ₁ 1, 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 SAM, AR SAM. SAM AR 40,SAM 6 6, AR,ARjet, SAM. AR 3, 2, 1.ARjet 63 5 mm, 64 9.SAM,. AR SAM, AR,. ₃ ₂ 1, 2, 2, 2, 1 1, 2..,,,.,PISA,vena contracta, reversal flow..,.,.,,.,.,,. ₃ ₃ 2 1, 2, 2, 2, 2, 2, 2, 1, 1, 1 1, 2 CHADS IMT 1. 1 mm, 15 mm 45 mm PS. PS 92 ; 70. 5, PS ; 12. 3, CHADS 2 ; 2. 3.CHADS 2 PS r 0. 44,p CHADS 2 0 PS; CHADS 2 3 PS; PS. CHADS 2,. ₃ ₄ 1, 2, 2, 1, 1, 1, 1, 2, 1 3, 1 4 1, 2, 3, 4 70.,,.. EF 33,,.,. PSV 277 cm/s,edv cm/s,rar 3. 31, AT 150 ms,.. PSV 181 cm/s,rar 1. 98, AT 60 ms.,,. 12
13 ₁ 1, 1, 1, 1, 2, 3, 1 1, 2 &, 3. ₂ 1, 1, 1, 1, 1, 2, 2, 2 1, 2,., 23.,.MRI,.,.,,,. ₃ 1, 1, 2, 2, 2 1, 2 Modality fusion,ge Volume Navigation V-Navi GPS 3D-US, fusion., 3D, fusion.. 20.,,,. ₄ 1 2, 2, 3, 1 2, 1, 2, 1 2, 1 2, 1, 1 1, 2, 3 Neuroendocrine carcinoma. 49,.. Neuroendocrine carcinoma ER,PgR, HER-2,Ki-67 : 40. Bp Ax.T 1 N 0 M 0 StageI. 50 Gy,2 LH-RH 5 Tamoxifen. 10, C 12 mm,. MRI.... Neuroendocrine carcinoma ER, PgR,HER-2,Ki-67 : 50,T 1 N 0 M 0 StageI. ₅ , 1 3, 2, 3 1 JA, 2, 3,E., US,2 CE ,C,, 3 cm.us CE 36 mm.,,,., US. ₆ 1, 1, 1, 1, 2, 2, 2 1, CT,,,,, CT 13
14 .CT,,,, MRI,US. MRI,,., target,,., IMT.IMT, IMT. ₇ 1, 1, 2, 3, 1 1 JMA, 2 JMA, , cm,,.mmg Ⅰ.US mm,,,,,d W 0. 53, US. CT US mm,d W US. ₁ 1 1 2, 2, 3, 1, 1, 2, 1 2, 1 2, 1, 1 1, 2, 3 FAP. 41,.15 FAP.23,.,.35 CT. Class V..,T 3,N 1 b 8 / 16,M 0 stage I., no 6,38.40, Lenvatinib, 9,PR.FAP,. ₂ 1 1, 2, 2, 2, 2, 2, 1, 1, 1, 1 1, 2 72,.. 70, MALT.,,.,5.,,diffuse large B-cell lymphoma. R-CHOP,,.,... ₃,,,,, 48,.,.US 29 mm halo.,.,.40 US,., mm mm 2 mm mm mm 7 mm mm,28 23 mm,6 mm,.6,.,,. ₄ 1 1, 2, 1, 1, 1, 1, 1, 1, 3, 2 1, 2, ,,.,.,,.MRI,. T 1 WI,T 2 WI,. 14
15 ,metastatic adenocarcinoma.ct spicula,.,. adenocarcinoma,. 1. ₅,,,,,, 26.17, , 3 cm, mm.,,.,.,,,,.,.. ₆ 1, 2, 3, 2 1, 2, 3,.,,., 31, 30, 38 3, 5 MHz,.,,.,.,. ₁,,, : 29. 1, 597 : NT NT 3. 5 mm 32 : 3. 8, 20 NT 13 : 2. 4, 50 NT 2 : NT 20, 1, 27, NT 8 4, 2. NT,,. ₂,,,,,. ₃ 1, 2, 1, 1, 1, 3 1, 2, 3. ₄ 1,,,,,,,,,, , mm,,., ureteropelvic junction stenosis: UPJ stenosis. 33, , 458 g,,apgar score 1 8,5 9., UPJ, 2,UPJ.,.. ₅ 1, 2, 1, 1, 1, 1, 1, 1, 3, 3 1, 2, 3., cm, AFI: ,34,. 36,,37.2, 637 g, Apgar score: 8 / 9 1 / 5,., 15
16 , ,,. ₁ 1 1, 2, 1, 1, 3, 1 1, 2, 3 Wunderlich,,.,. 14 2,.US.,,. MRI Wunderlich,. US,,,,.,. Wunderlich.US Wunderlich. ₂,,,,,,,,,, 8. 30,7,6. 8 6,,.,,.,,,..,, hcg,.,,,.,. ₃ 1,,,,, AVM,,.., ,..Hb 5. 0 mg/dl.,.3d-ct angiography..,... ₄,,,, UAP,, ,,., UAP,. 36, ,3 14 mm.doppler mode to-and-fro sign,uap.doppler.,,, UAP.UAP,. ₁ , 2, 1, 1, 1, 1, 1, 2, 3 1, 2, 3 AML,6 RCC US, mm,ct AML mm, mm, mm.,ct, mm, US CT.MRI, RCC,. pt1a.rcc US. RCC AML. AML RCC,. 16
17 ₂ 1, 2, 1, 3, 3 1, 2, 3, ,,,,,,,. 1 A, B. A B 20 19, 80, ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 64,. US,CT.. US mm.,,,.. CT,..,..,,.US,,.. ₄ 1 1, 2, 2, 1, 2, 1 1, 2 17,.,, mm.,.,..,.,. 1.. ₁ 1, 1, 2, 3, 2 1, 2, 3,,,.,. 250 MHz, 7 μm,.,,,.,,.,. ₂ 1, 1, 2, 3, 4, 2 1, 2, 3, 4,,., 5, 5,, 15 MHz,25 MHz,.,.,, μm, 1.,., 2,. 17
18 ₃ 1, 1 2 3, 3, 3 1, 2, 3.,USE MR MRE.., ACUSON S3000,Siemens VTQ VTIQ,3 T MRI MAGNETOM Verio,Siemens Hz MRE Vs. 2 cm Vs,VTQ VTIQ,MRE , , , Vs. 18
問 題 1 ₁ ₃ ₅ ₂ ₄ ₆ 問 題 2 ₁ ₂ ₃ 問 題 3 ₁ ₂ ₃ ₄ ₅ 2 2
問 題 1 ₁ ₃ ₅ ₂ ₄ ₆ 問 題 2 ₁ ₂ ₃ 問 題 3 ₁ ₂ ₃ ₄ ₅ 1 問 題 1 ₁ ₃ ₅ ₂ ₄ ₆ 問 題 2 ₁ ₂ ₃ 問 題 3 ₁ ₂ ₃ ₄ ₅ 2 2 問 題 1 ₁ ₃ ₅ ₂ ₄ ₆ 問 題 2 ₁ ₂ ₃ 問 題 3 ₁ ₂ ₃ ₄ ₅ 3 問 題 1 ₁ ₃ ₅ ₂ ₄ ₆ 問 題 2 ₁ ₂ ₃ ₄ 問 題 3 ₁ ₂ ₃ ₄ ₅ 4 4 問 題
41-6_35回中部地方会Pr6N_HP掲載用.indd
₃₅ 2014 9 7 ₃₅ ₁ 1, 1, 2, 1, 1, 1, 3, 3, 3 1, 2, 3., e E E/e. CT 158,CT Volume data, CT -140-40 HU. E e, e E/e. e,e/e,. ₃₅ ₂ 1, 1, 1, 1, 2, 2, 3, 2, 2 1, 2, 3 82, T,.. S, 13 mmhg,,, 10γ S 260 mmhg,. S,.,
抄録36-6偶_中国_責.indd
45 21 9 12 1 45-1 3D 1 5 10 1 1 12 0 13 6 2D 2 2 3D 1 14 2 63g 11cm 2 3D x 3DCT 1 3D 45-2 FIUVV 3 10 FIUVV IUFD 2 FIUVV 33 35 MRI 36 8 22 1cm FIUVV 28 IUFD 45-3 Fetal intra-abdominal umbilical vein varixfiuv
092_41-1_23九州CS6_責.indd
2013 10 6 1, 2 3 4, 5, 4, 6, 3, 5, 1, 1 1, 2, 3, 4, 5, 6,70. 2011 7 CT, B C, -GTP,CEA CA 19-9.US,S 2 / 3 43 37 mm,. 11 mm,,.ceus,.,.,. 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 52. S 7 20 mm,. CT, CT, EOB MRI,T
41-6_50回中国地方会Pr6N__HP掲載用.indd
2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.
084_41-1_23四国CS6_念*.indd
2013 10 5 The forgotten chamber.,,,.1.2,,, 3,,. 4,CT,MRI,,,,,,,, fractional area change: FAC,,M tricuspid annular plane systolic excursion: TAPSE TAPSE < 16 mm., s, speckle tracking, Tei index,,,.,,,.,6,.,,,,,
049_41-1_43北海道CS6_念*.indd
25 10 19 11 : 00 18 : 00,,,,, Meyer et al. Circulation 2010;121:252-258,ASE J Am Soc Echocardiogr 2010;23:685-713., ASE 3 1, 10, 2 36, 3 38.ASE TAPSE,RVFAC,S. 1 / 2 / 3 TAPSE 8. 4 / 10. 0 / 24. 4 mm 16
42-2_26回関東甲信越地方会Pr6N_念*.indd
2014 10 18 19 TFT acoustic radiation force ARALA TI MI TI / MI TI / MI 1 2 3 4 5 1 2 3 4 5 PZT MASON 20 MRayl 20 MRayl 10 500 khz 20 MHz 1 mw 15 W 500 khz 20 MHz 100 W 60 MHz 1 2 3 4 5 4 6 6 4 1 2 3 4
ⅠⅠ 1 Ⅰ Ⅰ 2 Ⅰ 3 Ⅰ Ⅰ Ⅰ 4 Ⅰ 4 Ⅰ Ⅰ Ⅱ Ⅲ Ⅰ Ⅲ 1 791
790 10 Ⅰ Ⅰ Ⅰ) Ⅰ) Ⅰ Ⅰ Ⅱ Ⅱ ⅡⅡ Ⅱ Ⅱ 27 12 20 ⅠⅠ 1 Ⅰ Ⅰ 2 Ⅰ 3 Ⅰ Ⅰ Ⅰ 4 Ⅰ 4 Ⅰ 16 20 27 Ⅰ Ⅱ Ⅲ Ⅰ Ⅲ 1 791 2 1 1 2 1 1 1 2 11 18 16 00 16 40 200 18 2 000 792 17 175 175 14 24 60 2 2 ₅ 3 793 1 ₇ 1 ₆ 2 1 ₂₁₁ 1 Ⅱ 1 28
抄録_46回中国地方会37-6_責.indd
46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density
ÿþ
YV-18 YV-19 YV-20 HALS Surgrx Enseal System 5 29 16:10 17:10 1-1 YP-1 YP-2 YP-3 YP-4 YP-5 YP-6 1 20 TS1 2 5 29 16:10 17:10 1-2 YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN 1 4 3 2 Gemcitabine 5 29 16:10 17:10
★プログラム並べかえ.indb
1 2 3 1 S180 S181 S182 S183 2 3 S184 S185 MRI S187 S188 S189 1 2 1 2 S 37 B flow imaging 1 1 1 2 1 1 S190 2 IVUS 1 2 3 4 5 1 2 S191 3 4 5 : MDCT MRI DSA S192 1 1 1 2 1 2 MR MRI FUS HIFU S194 S195 S196
03-07プ_一般口演_責*.indd
バブル キャビテーション 一 般 口 演 基 礎 5 月 9 日 ( 金 ) : 0-5 : 0 第 6 会 場 ( + ) 座 長 : 87- 基 -00 S6 87- 基 -00 S6 87- 基 -00 S65 87- 基 -00 S65 87- 基 -005 S66 組 織 音 響 特 性 5 月 9 日 ( 金 )5 : 50-7 : 00 第 6 会 場 ( + ) 座 長 : 87-
11 第25回がん学会一般演題一覧（第3会場）
1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP
32, 15, 3 EUS TIC 1 db,eus EG SR EUS 60, 27, 24 EUS EG SR 0. 11, , EUS EUS EG ₂₆ ₆ 1, 2, 1, 1, 3, 2, 4, 1 1, 2, 3, 4 FibroScan,
₂₆ 2016 10 2 ₂₆ ₁ 1, 2, 2, 2, 2, 1, 2, 5, 3, 4 1, 2, 3, 4, 5., 491,. 491 339, 70 37 152 3, 339 2,.,. ₂₆ ₂ 1, 1, 1, 1, 1, 1, 2, 2, 1 1, 2 Müller MM, LVESVMM LVESV Ees DCM 20 15 CPX,LVESV, Ees,peak- VO 2
8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2
vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.
C79 A11 A12 A13 A19 B11 B12 B13 B14 B15 B19 B21 B22 B23 B24 B25 C11 C12 C19 C21 C31 C32 C33 C34 C35 C36 C37 C39 C41 C51 C52 C53 C54 C55 C61 ( ) C62 C6
C79 A11 A12 A13 A19 B11 B12 B13 B14 B15 B19 B21 B22 B23 B24 B25 C11 C12 C19 C21 C31 C32 C33 C34 C35 C36 C37 C39 C41 C51 C52 C53 C54 C55 C61 ( ) C62 C63 C64 C71 C72 C73 C74 C99-1 - A11 A12 1 1 A13 A19 11
02_特別_共同_奨励.indb
特別プログラム 2 領域横断特別プログラム 知を究める領域横断 シンポジウム領域横断 超音波で全身を見る 6 月 8 日 ( 金 )0:5 - :45 第 9 会場 ( 神戸ポートピアホテル B F 偕楽 2) 座長 : 9 知 -SY- 領 0 S80 2 2 9 知 -SY- 領 02 S80 9 知 -SY- 領 0 S8 9 知 -SY- 領 04 S8 2 2 9 知 -SY- 領 05
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
04_学術.indd
Arts and Sciences 2 Diagnostic significance of contrast-enhanced ultrasonography for hepatocellular adenoma: experiences of two cases 41080 Key words: Abdominal ultrasonography Contrast-enhanced ultrasonography
03_一般.indb
基礎一般口演 一般口演基礎 マイクロバブル キャビテーション 6 月 8 日 ( 金 )8:0-9:0 第 会場 ( 神戸ポートピアホテル B F 生田 ) 座長 : 9- 基 -00 S566 Marie Pierre KRAFFT 9- 基 -00 S566 Marie Pierre KRAFFT Institut Charles Sadron CNRS, University of Strasbourg
169_39-2_23関東甲信越_念*.indd
2011 10 29 30 TFT infective endocarditis IE IE vegetation 10 20 IE IE Duke 1 1 1 1 2 2 1 2 1 1 5 US 1 mammography MMG 2 2 a second look US 0. 4 mm US b MMG 17 15 US MMG cse ASVascularity SE AS Vascularity
,. Elastgraphy.,.,,.. Elastgraphy,. SY Kupffer 1 2 3, 2, 2, 2, 2, 3, 3, 3, 4, 2 3 1, 2, 3, 4,.,,B mode.fibroscan 502 Controlled Attenuation Parameter
2016 10 29,, 1 2 3 4 EUS. 1 CT MRI, safety margin US-US fusion.,vincent TACE. 2.,., EOB-MRI, EOB- MRI,, Kupffer.. 3,. 4 EUS,,,., Kupffer,. SY - initial minutes Ultrasonography in the gastrointestinal disease
FC p07
GZ 1 2 L2 GE-R-KEG S1 2 I1 R (BSPT) thread 1 WE-R-KEG S3 I3 2 I2 1 RI-ED VSTIR-ED 1CA43 LEO-2 L - 24 O ISO 12151-2 - SWS W A C B mm mm mm mm mm 1CA43-6-4 6 M12x1,5-6 1/4-4 1.81 46-0.02-1 14 1.06 27 1CA43-8-4
68
BMG/BG 68 68 3 683 684 685 6 3 6 3 3 4 5 5 3 4 5 63 8 3 4 5 63 8 3 4 5 63 8 3 4 5 63 8 3 4 5 63 8 3 5 3 4 5 6 7 6 6 3 3 687 3 3 4 3 33 58 4 34 5 8 35 6 3 58! / 8 5 55 55 686 6 3 345 3455 55 6 6 3 3 3 4
V-SHIKA CATALOGUE vol.62
17 ST.200 A20,000 18,000 16,000 14,000 E 12,000 F 10,000 18 ST.201 A25,000 22,000 18,000 ST.205 20,000 19 ST.210 A16,000 12,000 10,000 9,000 E 8,000 ST.202 A27,000 24,000 21,000 20 ST.204 A20,000 17,000
VALQUA HAND BOOK 寸法編 2011
PDF 2010.9 Copyright 2010 NIPPON VALQUA INDUSTRIES,LTD. All Rights Reserved. ¹ ₈ ¹ ₄ ³ ₈ ¹ ₂ ³ ₄ ¹ ₄ ¹ ₂ ¹ ₂ ¹ ₂ ¹ ₂ ³ ₄ ¹ ₄ ¹ ₂ ¹ ₂ ¹ ₂ ¹ ₂ ³ ₄ ¹ ₄ ¹ ₂ ¹ ₂ ¹ ₂ ¹ ₄ ¹ ₂ ¹ ₂ ¹ ₂ ¹ ₂ ³ ₄
本文／一般演題＿吉田
184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
上水道工学 ( 第 5 版 ) サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. http://www.morikita.co.jp/books/mid/049285 このサンプルページの内容は, 第 5 版 1 刷発行時のものです. i 第 ₅ 版まえがき 1988 1 30 4 2012 5 2017 12 ii まえがき 62 100 93 1988 8 iii
1-24 acoustic neurinoma schwannoma T1 CT 13 Schwann Schwann T MRI T1 T2 14 T1 von Hippel-Lindau von Hippel-Lindau von Hippel-Lindau epidermo
MKSA X 6 MKSA 1kg 1 X 1.02MeV 0.51MeV X C/kg 1GyGray SvSievert 4 GyGray C/kg X X 5 X X X 3 SVSievert 0.51MeV contrast 2 X X 2 X 2 n 2 0.51MeV X n bit X 1-3 X 8 bit 2 8 3 X X X 256 sharpness X 110 130kVp
PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 m
2 2016 10 15 1, 2, 2, 2, 3, 3, 2, 4, 5, 4 1, 2, 3, 4, 5 I PH, PH PrePH PH PostPH, LVEF PostPH PEF-PostPH, PrePH PEF-PostPH, 25 mmhg, LVEF 45, 27, 15 mmhg PrePH 14 15 mmhg PEF-PostPH 13 TomTec 2D CPA, St
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
11.b a. b. 100% d. e. 12. b, e a. b. LET LET 30cGy/h(0.5cGy/min) G2 G2 () d. 1cGy/ 100cGy/ e.
1. 3.7GBq 1.3mSv 1/10 d 1 5 11.b a. b. 100% d. e. 12. b, e a. b. LET LET 30cGy/h(0.5cGy/min) G2 G2 () d. 1cGy/ 100cGy/ e. 13. a, c a. b. LET / d. LQ e. LQ 14. d, e a. b. d. e. 15. a NIPPON ACTA RADIOLOGICA
02-06プ_一般ポスター_0407.indd
一般ポスター工学基礎一般ポスター工学基礎 イメージング 信号処理 5 月 7 日 ( 土 )6:0-7:0 ポスター 展示会場 座長 : ( 栃木県総合文化センター 階第 4 ギャラリー ) 90- 基 P-00 CT S6 90- 基 P-00 S6 90- 基 P-00 S6 90- 基 P-004 S6 90- 基 P-005 S64 90- 基 P-006 S64 90- 基 P-007 STC
untitled
5 1.() 2.() 3.(JA ) 2 3 4 5 6 7 8 9 10 11 12 13 1,000m 165.52km2 1,200-1- H15.8.1 1,163 2,121 278 H19.2.1 60 12 8 15 13 4 10 14 4 13 15 16 22 16 12 21 44 81-2- - 0 - - 1 - - 2 - - 3 - - 4 -
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
04_ポスター.indb
般ポスター基礎超音波計測一般 一般ポスター基礎 6 月 8 日 ( 金 ):00 - :0 ポスター会場 ( 神戸ポートピアホテル B F 座長 : 9- 基 P-00 S790 9- 基 P-00 S790 9- 基 P-00 S79 Jing ZHU, 9- 基 P-00 S79 9- 基 P-005 S79 9- 基 P-006 CT S79 Wenjing WU 9- 基 P-007 HIFU
22肝胆膵_抄録_1_ indd
001 5 26 11:30 12:30 9-1 PO001-1 PO001-2 I II 2cm MRI PO001-3 PO001-4 PO001-5 PO001-6 5cm (Vp3/4,Vv2/3) PO001-7 1 PO001-8 B HCC C HCC B HCC PO001-9 002 5 26 11:30 12:30 9-1 PO002-1 HDAC PO002-2 Down Staging
[A](2): [B](4): DNA [B] [B](4):
: [B](4): DNA [B] [B](4):](/thumbs/91/104797401.jpg "[A](2): [B](4): DNA [B] [B](4):")
3 [A](2): 7 6 19.4 16.7 [A] 0 0.0 1 2.8 1 2.8 13 [A](1): 36.1 1974 1 3.0 2 5.6 1975 1 3.0 2 5.6 1980 1 3.0 4 11.1 1990 1 3.0 0 0.0 1993 1 3.0 36 100.0 1994 1 3.0 1999 1 3.0 [A](2): 2000 1 3.0 2001 5 15.2
untitled
5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm
ニチベイ 高遮蔽ブラインド セレーノグランツ 25・35
Glanz 2015 61 3 6.5 3 35mm 3 300cm400cm 6.5 1cm 35mm 35mm 25mm 25 35 C059S C011S C472S C471S C474S C473S C476S C475S C410S C411S C211S C210S C012S C061S C209S C413S C063S C407S C051S C013S C054S C408S
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
長崎県県央保健所事業概要
P1 P2~P3 P4 P5 P7~P10 P11~P40 P41~P174 P175~P179 P181~P212 271,417 2 3 4 5 5 7 8 9 10 12 13 14 15 16 18 19 2,506 365 293 5 20 2 4 123 4 17 1 2 143 351 5 3 18 40 10 475 3 2 22 22 66 1 13 18 31 10
抄録37-2関西36_責.indd
36 21 10 3 36-D-1 36-D-2 / 36-D-3 Heart failure with preserved EF : HF-PEF EF S : 255 EF 45% HF-PEF n=45efs 50mm n=2551mm n=20 : EF S S : 7.0±1.1 vs. 5.3± 1.3 cm/s, p
: 1 : 50 mm : RCC 4 FFP ml 2. 1 : MRI : T2 6 cm flow void : Gd T1 UAE UAE 4 57
34, 25-30, 2014 0.05 5.3% UAE TCR MTX 2013 7 1 11 31 4 1 36 1 1 2011 10 39 1 5 1 50 mm 1, MRI MRI T1 T2 flow void Gd T1 2, 50 UAE TCR 50 mm 700 ml 3 10 1 26 1. 1 : 1 : 50 mm : 3 2 36 4 2 2 2 13 49 RCC
「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について（第1報）」について
2012 3 28 2011 3 1 1 2012 3 2012 3 28 2012 3 28 2012 3 28 2012 3 28 1. 1 3 11 1 2 3 15 17 3 4 5 1 2012 3 28 5 10 6 3 18 7 5 8 3 23 9 2 2012 3 28 2011 3 23 23 10 3 2012 3 28 4 2012 3 28 5 2012 3 28 3 24
_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
a 1) 2) IVUS 3)1 7 1) 2) 3) 4) a)134 )12 c)23 d)4 )1~4 c (18 p95) 8 1) 7.5MHz 2) 4 ( ) 3) 4) a)134 )12 c)23 d)4 )1~4 d 9 1) - 2) - 3) - DDR 4)
H18 http://plaza.umin.ac.jp/~wiki/cgi-in/ 1 1) 2) 3) 4) a)134 )12 c)23 d)4 )1~4 4 = = (18 p47) 3 A~D a~ 1)A- 2)B- 3)C- 4)D- a)134 )12 c)23 d)4 )1~4 18 3 4 a~ 1) - 2) - ( ) 3) - 4) - a)134 )12 c)23 d)4
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
PII S (96)
C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s
http://www.ike-dyn.ritsumei.ac.jp/ hyoo/wave.html 1 1, 5 3 1.1 1..................................... 3 1.2 5.1................................... 4 1.3.......................... 5 1.4 5.2, 5.3....................
1
1 100 50/60Hz 100 50/60Hz 2 3 4 Windows 4.0SP3 Windows98 4.0SP3 800600 256 1024768 SETUP.EXE 5 [ ] 6 [ OK] [ ] 7 [ OK] [ ] 8 [ OK] [ ] 9 [ ] [ ] [ ] Enter Enter Windows Alt MP-60 10 [ ] F4 [ ] [ ] [ ]
book.pdf
B O N D DIY PRODUCTS 1 2 3 INDEX 37 2way 1 #04920 26 B1 3kg P #41947 13 500g #40117 14 CH18 1kg #40127 P 3kg #40140 14 CH18 5kg P #40177 14 CH18750 750g #40167 14 CH20 3kg P #40240 14 CH35 3kg P #40640
1 2 3 P
BL00004725-105 JA DIGITAL CAMERA X-Pro2 http://fujifilm-x.com/x-pro2/ Version 3.10 Q Fn http://fujifilm-dsc.com/manuals/ 1 2 3 P y P y P y P y P y P Q R P D P Q Fn Q P 57 Q Q BASE P 60 Q Q P 142 MENU/OK
( )
() 2006 2 16 1 () 2006 2 LinuxLinuxHPLinux(http://www.hp.com/jp/linux/) Linux 10000 10000 ProLiant 19 EIA 9000 1000mm 10000 G2 3 10000 G1 S10614 S10614 (14U) 292302-B22 130,000 ( 136,500 ) / () ProLiant
*.{.._H2~P90...I050819
Consolidated Financial Statements 102 104 105 106 108 129 101 3 31 2004 3 31 9......... 338,697 153,516 59,992 552,205 2004 480,123 109,941 6,809 596,873 1 $ 3,165,393 1,434,729 560,672 5,160,794.........
untitled
96 E-mail mizumi@tokyo-med.ac.jpmed.ac.jp 2008.6.28 1. 2. 3. 4. vs. 5. 6. 12, 16 Poroma / vs. 1. decapitation secretion apocrine snout apical snout pinching-off fringe 2. 3. 4. 5. 6.
サーバ製品 システム構成図 ( ラックオプション編 ) 2005 年 2 月 28 日 1
サーバ製品 システム構成図 ( ラックオプション編 ) 2005 年 2 月 28 日 1 () 2005 2 Linux Linux HP Linux (http://www.hp.com/jp/linux/) Linux 2004 6 3 MSA UPS 10000 10000 ProLiant 19 EIA 9000 1000mm S10614 S10614 (14U) 292302-B22
Microsoft Word - 01マニュアル・入稿原稿p1-112.doc
4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e
No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh
1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1
![1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1](/thumbs/49/25412084.jpg "1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1")
I, A 25 8 24 1 1.1 ( 3 ) 3 9 10 3 9 : (1,2,6), (1,3,5), (1,4,4), (2,2,5), (2,3,4), (3,3,3) 10 : (1,3,6), (1,4,5), (2,2,6), (2,3,5), (2,4,4), (3,3,4) 6 3 9 10 3 9 : 6 3 + 3 2 + 1 = 25 25 10 : 6 3 + 3 3
030801調査結果速報版.PDF
15 8 1 15 7 26 1. 2. 15 7 27 15 7 28 1 2 7:13 16:56 0:13 3km 45 346 108 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3. 3.1 26 7 10 1 20cm 2 1 2 45 1/15 3 4 5,6 3 4 3 5 6 ( ) 7,8 8 7 8 2 55 9 10 9 10
051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
43
43 HK4001 X X 1949 Paatero 1 X MTF MTF 10 m 3,6,9mm MTF MTF 3mm,6mm,9mm MTF MTF X HK4004 200nm 950nm 600nm 760nm 850nm 960nm OH 600 900nm 600nm 800nm 44 HK4006 JPEG2000 CTF HK4007 40 X Mo Mo MTF ACR156
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
ニトロトルエン
4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6
(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
1 2 3 P R
BL04700-101 JA DIGITAL CAMERA X-T1 Q Fn http://fujifilm.jp/personal/digitalcamera/index.html http://fujifilm-x.com/x-t1/ 1 2 3 P R y P y P y P y P Q R P V P Q Q Q Fn Fn1 Fn2 Fn3 Fn4 Fn5 Fn6 P S A M M
genron-3
" ( K p( pasals! ( kg / m 3 " ( K! v M V! M / V v V / M! 3 ( kg / m v ( v "! v p v # v v pd v ( J / kg p ( $ 3! % S $ ( pv" 3 ( ( 5 pv" pv R" p R!" R " ( K ( 6 ( 7 " pv pv % p % w ' p% S & $ p% v ( J /
JSACHD_Vol5_No3_Dec2016.book
5 3 12 16 (2016 ) Fontan 1) 2) 1) 2) Fontan circulation, Fontan associated liver disease, Liver fibrosis, Liver tumor, Central venous Pressure 25% I. FALD Fontan Fontan ( CVP) Fontan associated liver disease
¹₄ ³₈ ³₈ ¹₂ ¹₂ ¹₂ ³₄ ³₄
33 4 5 2 63 2 1 3 1 4 2 5 6 19 ¹₄ ³₈ ³₈ ¹₂ ¹₂ ¹₂ ³₄ ³₄ 1 1 5 6 6 7 1 1 1 1 1 1 35 GDC LB 1 1 Y 2 A54 2 1 2 1 1 5 1 1 21 1 2 2 2 53 512 53 53 512 3 12 2 2 4 5 63 1 1 2 4 5 63 1 1 2 45 1 5 2 3 4 4 3 4 4
MP-AES ICP-QQQ Agilent 5100 ICP-OES Agilent 5100 (SVDV) ICP-OES (DSC) 1 5100 SVDV ICP-OES VistaChip II CCD Agilent 7900 ICP-MS 7700 / 10 7900 ICP-MS ICP-MS FTIR Agilent 7900 ICP-MS Agilent Cary 7000 (UMS)
-1-
-1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- kw kw E-mail A4 A4 A4 24 6 22 E-mail 2 V kva kwkw kw Hz Hz *1 Hz 60 () () GD 2 kgm 2 () kgm 2 () MVA
28kses_program.indd
1-1 4 1 1-2 2 1-3 PTGBD LC 1-4 1-5 2-1 2-2 2-3 Solid-pseudopapillary neoplasm 2 3-1 1 3-2 HALS 3-3 3-4 Siewert type Double Tract 3-5 No.6 4-1 4-2 4-3 1 4-4 QOL Billroth I vs Roux-en Y 4-5 4-6 5-1 5-2 5-3
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
甲状腺(JABTS)一般口演 Department of Clinical Laboratory, Kitasato University Hospital 2 Department of Laboratory Medicine, Kitasato University School of Medi
一般口演般口演TS)一 甲状腺 (JABTS) 90 00 005 90 006 02 甲状腺(JAB 甲状腺(JABTS)一般口演 Department of Clinical Laboratory, Kitasato University Hospital 2 Department of Laboratory Medicine, Kitasato University School of Medicine
<90CE90EC88E290D55F955C8E862E656336>
5 5 9 9 7 7 5 5 6 6 7 7 8 8 9 9 8 8 8 8 79 79 78 78 76 76 77 77 7 7 6 7 7 5 68 68 67 67 66 66 65 65 6 6 6 6 6 6 6 6 6 6 59 59 58 58 57 57 56 56 55 55 5 5 8 8 5 5 9 9 9 8 7 9 9 8 8 7 7 6 6 5 5 5 5 69 69
岩手県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 IWATE 2 3 4 16 1 2 3 2 14 165.6 165.2 55.2 54.3 88.6 88.1 cm kg cm 13 160.1 159.7 50.1 49.1 85.1 84.9 12 153.5 152.5 46.3 44.2 81.9 81.3 13 155.4 154.9 48.9 47.3 84.2 83.7
59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1
59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl
4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2
5 2006 9 1 A) 1 2 3 4 B) 1 2 3 4 5 2 A) GDP 7.9 B) 31 25 8 10 1 45 3 31 8 2 70 1 4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2 1.6 3 31.1 4 2 5 3 4 CT MRI PET 1 30 A) 1 2 6 B) 1 2 3 4 5 3 90.5
評価結果報告書の概要版（平成20年度）
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
untitled
206.2 0.5 25+85 25V 25+60. 50mø 65mø 00 m OR 000Hz 2. 000Mø 00V 3. 250V 4. 5. 6. 7. 8. 9. 7 27 37 5 25N 30N 36N 43N 2.6N 3N 3.3N 3.8N 70mø 85mø 0µs 70mø 85mø 00Mø 000 055Hz0.75mm 5/0 490m/s 2 ms 33 55
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons
54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018
A a b c d a b a b c d e a b c g h f i d e f g h i M a b c a b c d M a M b c d a b a b a M b a b a b c a b a M a a M a c d b a b c d a b a b a M c d a b e c M f a b c d e f E F d e a f a M bm c d a M b
0 S S 1 P MSM0 MSM0 MSM0 3 MSM03 0 MSM00 0 MSM0 MSM BP MSB0 MSB0 MSB0 MSB03 MSB00 MSB0 MSB FFPFB MSF0 MSF0 MSF0 MSF03 MSF00 MSF0 MSF C MSC0 MSC0 MSC0
S S 3 0 0 0 3 0.01MPa 1.MPa 0s 0 JIS /g 1.0 0 SMBFFBCCBTTB SPMPPFPTP TTPTBCB 1 T1S YF F 0 0 0 0 0 M SSP MP 0 3..3. 3. 0.3 0.. 1 B P 0 10 3 0 0 F FP 3 0 3 FB 3 0 3 C 0 CB 1 T TP 1 3 TB 0 0 0 1 3 1 0 0 0
膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma